Jump to content

Julian Downward: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
split
Line 37: Line 37:


{{Francis Crick Institute}}
{{Francis Crick Institute}}
{{FRS 2005}}
{{Authority control}}
{{Authority control}}


Revision as of 23:51, 3 November 2016

Julian Downward

FRS FMedSci
Born (1960-10-25) 25 October 1960 (age 64)[1]
Scientific career
FieldsCancer biology[2]
ThesisThe structure and function of the receptor for epidermal growth factor (1986)
Doctoral advisorMichael Waterfield
Other academic advisorsRobert Weinberg
Websitecrick.ac.uk/research/a-z-researchers/researchers-d-h/julian-downward/

(David) Julian (Harry) Downward (born 25 October 1960)[1] FRS FMedSci is Associate Research Director at the Francis Crick Institute and Senior Group Leader at the Institute of Cancer Research.[3] He was formerly head of the Signal transduction Laboratory at the London Research Institute.[4][5][6][2]

Education

Downward was educated at Eton College and earned a Bachelor of Arts degree in Natural Sciences from Clare College, Cambridge.[1] His PhD was supervised by Michael Waterfield at the Imperial Cancer Research Fiund where he investigated Epidermal growth factor receptor.[7] From 1986 to 1989, he was a postdoctoral researcher with Robert Weinberg, at the Whitehead Institute for biomedical research at the Massachusetts Institute of Technology.[8] [9]

Research

Downward's research investigates cancer biology. His work on the Ras GTPase has made seminal contributions to our understanding of how cellular signal transduction pathways are subverted in oncogenic transformation. His work provided the first demonstration that Guanosine triphosphate-loading on Ras, which is commonly mutationally activated in human tumours, is normally regulated in response to extracellular factors; he went on to characterise growth factor receptor complexes mediating Ras nucleotide exchange, and to demonstrate that GTP-bound Ras binds to and activates the RAF kinase, which controls the mitogen-activated protein kinase pathway. Julian was first to demonstrate that phosphoinositide 3-kinase (PI 3-kinase) is also a Ras effector, important in regulation of apoptosis. He showed that transformation by Ras requires interaction with multiple effectors, which contribute differentially to cell cycle progression, cytoskeletal regulation and apoptosis. His more recent work has established that both cell matrix and cell–cell interaction activate the PI 3-kinase/PKB pathway, and thereby prevent programmed cell death, and that it is activation of this pathway by oncogenic Ras that allows anchorage-independent growth of transformed cells.[3][10]

Awards and honours

Downward was elected a Fellow of the Royal Society (FRS) in 2005.[3] He was also elected Fellow of the Academy of Medical Sciences in 2009 and was a member of the Faculty of 1000 from 2001 to 2005.[11]

Personal life

Downard is the son of Major general Sir Peter Aldcroft Downward, KCVO, CB, DSO, DFC.[1][12][13]

References

  1. ^ a b c d DOWNWARD. "DOWNWARD, Prof. Julian". Who's Who. Vol. 2016 (online Oxford University Press ed.). Oxford: A & C Black. {{cite encyclopedia}}: Unknown parameter |othernames= ignored (help) (Subscription or UK public library membership required.) (subscription required)
  2. ^ a b Julian Downward publications indexed by Google Scholar
  3. ^ a b c "Dr Julian Downward FMedSci FRS". London: Royal Society. Archived from the original on 19 November 2015. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --Archived 2015-09-25 at the Wayback Machine
  4. ^ "Professor Julian Downward: Team Leader". London: Institute of Cancer Research. Archived from the original on 7 September 2015.
  5. ^ Downward, Julian (2003). "Targeting RAS signalling pathways in cancer therapy". Nature Reviews Cancer. 3 (1): 11–22. doi:10.1038/nrc969. ISSN 1474-175X.
  6. ^ Castellano, E.; Downward, J. (2011). "RAS Interaction with PI3K: More Than Just Another Effector Pathway". Genes & Cancer. 2 (3): 261–274. doi:10.1177/1947601911408079. ISSN 1947-6019.
  7. ^ Downward, David Julian Harry (1986). The structure and function of the receptor for epidermal growth factor (PhD thesis). University of London. OCLC 940270478.
  8. ^ "Julian Downward". rnaiglobal.org. Archived from the original on 4 March 2016.
  9. ^ J. Downward, J. de Gunzburg, R. Riehl & R. A. Weinberg (1988). "p21ras-induced responsiveness of phosphatidylinositol turnover to bradykinin is a receptor number effect". Proceedings of the National Academy of Sciences of the United States of America. 85 (16): 5774–5778. doi:10.1073/pnas.85.16.5774. PMC 281847. PMID 2901087.{{cite journal}}: CS1 maint: multiple names: authors list (link) Open access icon
  10. ^ Julian Downward: RAS and PI 3-kinase Signaling Networks in Cancer talk, presented at the 2010 Koch Institute Summer Symposium on YouTube
  11. ^ "Julian Downward". f1000.com
  12. ^ Kathleen Weston (2014). Blue Skies & Bench Space: Adventures in Cancer Research. Cold Spring Harbor Laboratory Press. ISBN 978-1-621820-77-2.
  13. ^ "Major-General Sir Peter Downward - obituary". The Telegraph. Archived from the original on 7 February 2016.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Julian_Downward&oldid=747717332"